HRP20190533T1 - Postupak za otkrivanje nukleosoma koji sadrže nukleotide - Google Patents

Postupak za otkrivanje nukleosoma koji sadrže nukleotide Download PDF

Info

Publication number
HRP20190533T1
HRP20190533T1 HRP20190533TT HRP20190533T HRP20190533T1 HR P20190533 T1 HRP20190533 T1 HR P20190533T1 HR P20190533T T HRP20190533T T HR P20190533TT HR P20190533 T HRP20190533 T HR P20190533T HR P20190533 T1 HRP20190533 T1 HR P20190533T1
Authority
HR
Croatia
Prior art keywords
dna base
body fluid
fluid sample
detecting
binding agent
Prior art date
Application number
HRP20190533TT
Other languages
English (en)
Inventor
Jacob Vincent Micallef
Original Assignee
Belgian Volition Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Belgian Volition Sprl filed Critical Belgian Volition Sprl
Publication of HRP20190533T1 publication Critical patent/HRP20190533T1/hr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)

Claims (9)

1. Upotreba baze DNK koja je povezana s nukleosomom bez stanica kao biomarkerom u uzorku tjelesne tekućine za dijagnozu raka, kardiomiopatije, sistemskog eritematoznog lupusa, kolitisa, kroničnog opstruktivnog plućnog poremećaja, Crohnove bolesti i reumatoidnog artritisa, naznačena time što je baza DNK odabrana od: 5-metilcitozina ili 5-hidroksimetilcitozina.
2. Upotreba kako je definirano u zahtjevu 1, naznačena time što je nukleosom bez stanica mononukleosom ili oligonukleosom.
3. Upotreba kako je definirano u zahtjevu 1 ili zahtjevu 2, naznačena time što se baza DNK koja je povezana s nukleosomom bez stanica mjeri u uzorku krvi.
4. Upotreba kako je definirano u bilo kojem od zahtjeva 1 do 3, naznačena time što se rak odnosi na rak mokraćnog mjehura, dojke, debelog crijeva, vrata maternice, jednjaka, bubrega, debelog crijeva, pluća, usne šupljine, jajnika, gušterače, prostate, rektuma kože ili želuca.
5. Postupak za otkrivanje prisutnosti baze DNK koja je povezana s nukleosomom bez stanica u uzorku tjelesne tekućine koji obuhvaća korake: (i) dovođenje u kontakt uzorka tjelesne tekućine s prvim sredstvom za vezanje koje se veže na nukleosome; (ii) dovođenje u kontakt nukleosoma vezanih u koraku (i) s drugim sredstvom za vezanje koje se veže na bazu DNK; (iii) otkrivanje ili kvantificiranje vezivanja navedenog drugog sredstva za vezanje za bazu DNK u uzorku tjelesne tekućine; i (iv) korištenje prisutnosti ili stupnja takvog vezanja kao mjere prisutnosti nukleosoma koji sadrže bazu DNK u uzorku tjelesne tekućine, naznačen time što je baza DNK odabrana od: 5-metilcitozina ili 5-hidroksimetilcitozina.
6. Postupak za otkrivanje prisutnosti baze DNK koja je povezana s nukleosomom bez stanica u uzorku tjelesne tekućine koji obuhvaća korake: (i) dovođenje u kontakt uzorka tjelesne tekućine s prvim sredstvom za vezanje koje se veže na bazu DNK; (ii) dovođenje u kontakt baze DNK vezane u koraku (i) s drugim sredstvom za vezanje koje se veže na nukleosome; (iii) otkrivanje ili kvantificiranje vezivanja navedenog drugog sredstva za vezanje za nukleosome u uzorku tjelesne tekućine; i (iv) korištenje prisutnosti ili stupnja takvog vezanja kao mjere prisutnosti nukleosoma koji sadrže bazu DNK u uzorku tjelesne tekućine, naznačen time što je baza DNK odabrana od: 5-metilcitozina ili 5-hidroksimetilcitozina.
7. Postupak kako je definirano u zahtjevu 5 ili zahtjevu 6, naznačen time što je sredstvo za vezanje protutijelo.
8. Postupak prema bilo kojem od zahtjeva 5 do 7, naznačen time što je uzorak tjelesne tekućine krv ili serum ili plazma.
9. In vitro postupak za otkrivanje ili dijagnosticiranje statusa bolesti kod životinje ili čovjeka koji obuhvaća korake: (i) otkrivanje ili mjerenje u tjelesnoj tekućini dobivenoj od subjekta baze DNK povezane s nukleosomom bez stanica; i (ii) korištenje otkrivene osnovne razine DNK povezane s nukleosomom za identifikaciju statusa bolesti kod subjekta, naznačen time što je baza DNK odabrana od: 5-metilcitozina ili 5-hidroksimetilcitozina, pri čemu je bolest odabrana od: raka, kardiomiopatije, sistemskog eritematoznog lupusa, kolitisa, kroničnog opstruktivnog plućnog poremećaja, Crohnove bolesti i reumatoidnog artritisa.
HRP20190533TT 2011-09-01 2019-03-19 Postupak za otkrivanje nukleosoma koji sadrže nukleotide HRP20190533T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161530295P 2011-09-01 2011-09-01
GBGB1115095.0A GB201115095D0 (en) 2011-09-01 2011-09-01 Method for detecting nucleosomes containing nucleotides
EP12756549.7A EP2751568B1 (en) 2011-09-01 2012-08-31 Method for detecting nucleosomes containing nucleotides
PCT/GB2012/052128 WO2013030577A1 (en) 2011-09-01 2012-08-31 Method for detecting nucleosomes containing nucleotides

Publications (1)

Publication Number Publication Date
HRP20190533T1 true HRP20190533T1 (hr) 2019-06-28

Family

ID=44882046

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190533TT HRP20190533T1 (hr) 2011-09-01 2019-03-19 Postupak za otkrivanje nukleosoma koji sadrže nukleotide

Country Status (22)

Country Link
US (2) US10900064B2 (hr)
EP (2) EP3483608B1 (hr)
JP (1) JP6322845B2 (hr)
KR (1) KR102074528B1 (hr)
CN (1) CN104067124B (hr)
AU (1) AU2012300641B2 (hr)
BR (1) BR112014005087B1 (hr)
CA (1) CA2845993C (hr)
DK (1) DK2751568T3 (hr)
ES (1) ES2717659T3 (hr)
GB (1) GB201115095D0 (hr)
HK (1) HK1199760A1 (hr)
HR (1) HRP20190533T1 (hr)
HU (1) HUE043386T2 (hr)
MX (1) MX364410B (hr)
PL (1) PL2751568T3 (hr)
PT (1) PT2751568T (hr)
RU (2) RU2014112350A (hr)
SG (2) SG10201601153RA (hr)
TR (1) TR201904386T4 (hr)
WO (1) WO2013030577A1 (hr)
ZA (1) ZA201401295B (hr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US10081839B2 (en) 2005-07-29 2018-09-25 Natera, Inc System and method for cleaning noisy genetic data and determining chromosome copy number
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US10083273B2 (en) 2005-07-29 2018-09-25 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
AU2009279734A1 (en) 2008-08-04 2010-02-11 Natera, Inc. Methods for allele calling and ploidy calling
WO2011041485A1 (en) 2009-09-30 2011-04-07 Gene Security Network, Inc. Methods for non-invasive prenatal ploidy calling
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
EP2572003A4 (en) 2010-05-18 2016-01-13 Natera Inc METHOD FOR NONINVASIVE PRANATAL PLOIDIE ASSIGNMENT
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
CA2821906C (en) 2010-12-22 2020-08-25 Natera, Inc. Methods for non-invasive prenatal paternity testing
BR112013020220B1 (pt) 2011-02-09 2020-03-17 Natera, Inc. Método para determinar o estado de ploidia de um cromossomo em um feto em gestação
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
EP2775304A1 (en) * 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
US10577655B2 (en) 2013-09-27 2020-03-03 Natera, Inc. Cell free DNA diagnostic testing standards
US10262755B2 (en) 2014-04-21 2019-04-16 Natera, Inc. Detecting cancer mutations and aneuploidy in chromosomal segments
WO2015048535A1 (en) * 2013-09-27 2015-04-02 Natera, Inc. Prenatal diagnostic resting standards
AU2015249846B2 (en) 2014-04-21 2021-07-22 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
WO2016049936A1 (en) * 2014-09-30 2016-04-07 Bgi Shenzhen Co., Limited Biomarkers for rheumatoid arthritis and usage therof
JP6721599B2 (ja) 2014-10-29 2020-07-15 ベルジアン ボリション エスピーアールエル 循環する腫瘍ｄｎａの濃縮方法
WO2016128383A1 (en) * 2015-02-10 2016-08-18 B.R.A.H.M.S Gmbh Free histone proteins as biomarkers
EP4428863A2 (en) 2015-05-11 2024-09-11 Natera, Inc. Methods and compositions for determining ploidy
US11111520B2 (en) 2015-05-18 2021-09-07 Karius, Inc. Compositions and methods for enriching populations of nucleic acids
GB201511542D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell free nucleosomes as biomarkers
GB201511512D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell-free nucleosomes as biomarkers
GB201518674D0 (en) * 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for detecting nuleosomes containing histone modifications and variants
GB201518665D0 (en) * 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for enrichment of cell free nucleosomes
GB201604806D0 (en) * 2016-03-22 2016-05-04 Singapore Volition Pte Ltd Method of identifying a cancer of unknown origin
CN107858416B (zh) * 2016-09-19 2021-05-28 深圳华大生命科学研究院 用于子宫内膜异位症检测的生物标志物组合及其应用
US11485996B2 (en) 2016-10-04 2022-11-01 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
CA3049139A1 (en) 2017-02-21 2018-08-30 Natera, Inc. Compositions, methods, and kits for isolating nucleic acids
CN107164508A (zh) * 2017-06-16 2017-09-15 上海易毕恩基因科技有限公司 用于检测肝癌的基因标志物及其用途
CN107385051A (zh) * 2017-08-04 2017-11-24 上海易毕恩生物技术有限公司 用于检测肝肿瘤良恶性的基因标志物、试剂盒及检测方法
WO2019118926A1 (en) 2017-12-14 2019-06-20 Tai Diagnostics, Inc. Assessing graft suitability for transplantation
CA3091807A1 (en) * 2018-03-01 2019-09-06 Epicypher, Inc. Quantification of nucleosome modifications using chemically-defined recombinant nucleosomes
EP3781714A1 (en) 2018-04-14 2021-02-24 Natera, Inc. Methods for cancer detection and monitoring by means of personalized detection of circulating tumor dna
US11525159B2 (en) 2018-07-03 2022-12-13 Natera, Inc. Methods for detection of donor-derived cell-free DNA
GB201818965D0 (en) 2018-11-21 2019-01-09 Belgian Volition Sprl Method for the detection of colorectal cancer
GB201818963D0 (en) 2018-11-21 2019-01-09 Belgian Volition Sprl Methof for the detection of prostate cancer
GB201906199D0 (en) 2019-05-02 2019-06-19 Belgian Volition Sprl Method for the detection of cancer
GB201906201D0 (en) 2019-05-02 2019-06-19 Belgian Voltion Sprl Method for the detection of protate cancer
GB201912251D0 (en) 2019-08-27 2019-10-09 Belgian Volition Sprl Method of isolating circulating nucleosomes
AU2020336928A1 (en) 2019-08-27 2022-03-24 Belgian Volition Srl Method of isolating circulating nucleosomes
MX2022006655A (es) 2019-12-02 2022-09-07 Belgian Volition Srl Uso de nucleosomas libres de celulas como biomarcadores.
AU2021238782A1 (en) 2020-03-20 2022-09-22 Belgian Volition Srl Triaging method using cell free nucleosome levels
TW202238131A (zh) 2020-11-25 2022-10-01 比利時商比利時意志有限公司 測量無細胞核蛋白染色質片段之方法
TW202242145A (zh) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析
TW202242130A (zh) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 循環轉錄因子分析
TW202242146A (zh) 2021-01-13 2022-11-01 比利時商比利時意志有限公司 肺癌的檢測方法
GB202108185D0 (en) 2021-06-08 2021-07-21 Belgian Volition Sprl Standardisation of nucleosome assays using biologically derived calibrants
GB202108452D0 (en) 2021-06-14 2021-07-28 Belgian Volition Sprl Triaging method using cell free nucleosome levels
WO2023073179A1 (en) 2021-10-29 2023-05-04 Belgian Volition Srl Homogeneous immunoassay method
GB202117799D0 (en) 2021-12-09 2022-01-26 Belgian Volition Srl Method for the detection of blood cancer
WO2023170298A1 (en) 2022-03-11 2023-09-14 Belgian Volition Srl Differential diagnosis method
GB202205212D0 (en) 2022-04-08 2022-05-25 Belgian Volition Sprl Method for transplant organ health assessment
WO2024042210A1 (en) 2022-08-25 2024-02-29 Belgian Volition Srl Method for measuring cell free chromatin
WO2024133222A1 (en) 2022-12-19 2024-06-27 Belgian Volition Srl Assessment of biological samples for nucleic acid analysis
GB202300607D0 (en) 2023-01-16 2023-03-01 Belgian Volition Srl Proteins and methods for isolating circulating nucleosomes
GB202303562D0 (en) 2023-03-10 2023-04-26 Belgian Volition Sprl Sample collection for liquid biopsy

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2652901A1 (fr) 1989-10-11 1991-04-12 Pasteur Institut Complexes biologiques a base de nucleosomes, et leurs applications, notamment dans le domaine du diagnostic in vitro du lupus erythemateux dissemine (led).
US6630301B1 (en) * 1997-03-14 2003-10-07 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum
US6329179B1 (en) * 1996-03-26 2001-12-11 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
WO1999047924A1 (en) 1998-03-18 1999-09-23 Roche Diagnostics Gmbh Detection of apoptotic products
NL1014106C2 (nl) 2000-01-18 2001-07-20 Univ Amsterdam Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit.
WO2005003381A1 (en) 2003-07-04 2005-01-13 Johnson & Johnson Research Pty. Limited Method for detection of alkylated cytosine in dna
GB0319376D0 (en) * 2003-08-18 2003-09-17 Chroma Therapeutics Ltd Histone modification detection
WO2005040814A1 (en) * 2003-10-14 2005-05-06 Cancer Research Technology Limited Methods and means of cancer detection by histone modification
AU2005322312B2 (en) * 2004-12-16 2011-05-26 President And Fellows Of Harvard College Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
DE102005034628B4 (de) 2005-07-19 2007-08-23 Epigenomics Ag Verfahren zur Untersuchung von Cytosin-Methylierungen in DNA
WO2007049286A1 (en) * 2005-10-27 2007-05-03 Tata Memorial Centre A system for ex-vivo separation of apoptotic chromatin particles from blood or plasma
US20090264306A1 (en) 2005-10-27 2009-10-22 Curators Of The University Of Missouri Dna methylation biomarkers in lymphoid and hematopoietic malignancies
WO2007076200A2 (en) 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof
DE102006035600B3 (de) 2006-07-27 2007-11-08 Epigenomics Ag Verfahren zum Nachweis eines Methylierungsmusters
US20080131954A1 (en) * 2006-11-30 2008-06-05 Canon U.S. Life Sciences, Inc. Method of Separating Target DNA from Mixed DNA
EP2147124A4 (en) 2007-04-11 2010-07-14 Manuel Esteller EPIGENETIC BIOMARKERS FOR EARLY DETECTION, EFFICIENT TREATMENT AND RETENTION OF CANCER
US7608402B2 (en) * 2008-01-10 2009-10-27 Weiwei Li DNA methylation specific signal amplification
WO2009115313A1 (en) 2008-03-19 2009-09-24 Oryzon Genomics, S.A. Method and composition for methylation analysis
SI2865387T1 (sl) 2008-11-21 2019-10-30 Kobenhavns Univ University Of Copenhagen Primiranje imunskega odziva
US20120094949A1 (en) 2009-04-14 2012-04-19 The Regents Of The University Of California Histone modification patterns for clinical diagnosis and prognosis of cancer
EP2462245B1 (en) 2009-08-06 2016-10-05 Cornell University Device and methods for epigenetic analysis
US20130183662A1 (en) 2010-04-22 2013-07-18 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations
WO2011150974A1 (en) 2010-06-03 2011-12-08 Porto Conte Ricerche S.R.L. Biomarkers for lung neuroendocrine tumors
FI20105715A0 (fi) 2010-06-18 2010-06-18 Helsingin Yliopisto Asetyloituun HMGB1:een sitoutuva polyklonaalinen vasta-aine
CN101955998A (zh) * 2010-07-20 2011-01-26 赵英仁 一种血浆游离dna水平检测肝细胞坏死程度的方法
GB201115098D0 (en) * 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
BR112014013082B1 (pt) * 2011-12-07 2021-02-02 Singapore Volition Pte Limited uso de um aduto nucleossomo-proteína e métodos para detectar a presença de um aduto nucleossomo-proteína
ES2930180T3 (es) 2012-03-02 2022-12-07 Sequenom Inc Métodos para enriquecer ácido nucleico canceroso a partir de una muestra biológica
GB201303575D0 (en) 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for detecting histone modifications in nucleosomes

Also Published As

Publication number Publication date
CA2845993C (en) 2020-10-13
RU2017126701A3 (hr) 2019-01-31
JP6322845B2 (ja) 2018-05-16
EP3483608B1 (en) 2023-06-07
HK1199760A1 (en) 2015-07-17
KR102074528B1 (ko) 2020-02-06
US10900064B2 (en) 2021-01-26
ES2717659T3 (es) 2019-06-24
US20200347435A1 (en) 2020-11-05
PT2751568T (pt) 2019-04-16
AU2012300641B2 (en) 2017-09-28
US20140363812A1 (en) 2014-12-11
DK2751568T3 (en) 2019-04-15
CA2845993A1 (en) 2013-03-07
BR112014005087B1 (pt) 2020-12-22
CN104067124A (zh) 2014-09-24
RU2687483C2 (ru) 2019-05-14
TR201904386T4 (tr) 2019-05-21
AU2012300641A1 (en) 2014-03-06
EP2751568A1 (en) 2014-07-09
MX2014002443A (es) 2014-10-13
SG11201400270PA (en) 2014-03-28
ZA201401295B (en) 2014-12-23
PL2751568T3 (pl) 2019-09-30
KR20140078637A (ko) 2014-06-25
RU2017126701A (ru) 2019-01-31
HUE043386T2 (hu) 2019-08-28
EP3483608A1 (en) 2019-05-15
BR112014005087A2 (pt) 2017-03-28
WO2013030577A1 (en) 2013-03-07
GB201115095D0 (en) 2011-10-19
SG10201601153RA (en) 2016-03-30
RU2014112350A (ru) 2015-10-10
CN104067124B (zh) 2018-05-04
MX364410B (es) 2019-04-25
JP2014531573A (ja) 2014-11-27
EP2751568B1 (en) 2018-12-26

Similar Documents

Publication Publication Date Title
HRP20190533T1 (hr) Postupak za otkrivanje nukleosoma koji sadrže nukleotide
JP2014529405A5 (hr)
JP2014531573A5 (hr)
JP2017215338A5 (hr)
JP2008536098A5 (hr)
RU2014112348A (ru) Способ детекции нуклеосом, содержащих гистоновые варианты
JP2008529008A5 (hr)
JP2018536849A5 (hr)
BRPI1007321A2 (pt) métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo.
WO2014140933A8 (en) Method for the prognosis and treatment of cancer metastasis
ATE554389T1 (de) Apex als marker für lungenkrebs
WO2009121024A3 (en) Methods for detecting antibodies
JP2019516104A5 (hr)
JP2018529931A5 (hr)
JP2016519767A5 (hr)
FR2919061B1 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
JP2017524933A5 (hr)
HRP20200229T1 (hr) Uporaba izvanstaničnih nukleosoma kao biomarkera u fekalnim uzorcima
BR112013005977A2 (pt) polipeptídeo isolado, anticorpo contra efrina-b2 e sua utilização, ácido nucleíco; vetor; célula; método de obtenção do polipeptídeo ou do anticorpo; método de detecção e/ou quantificação da efrina-b2; método de diagnóstico de uma enfermidade associada a expressão da efrina-b2; composição e sua utilização
WO2011159741A3 (en) Tetranor-pgem/pgam specific immunogens, antibodies, tracers, assay kits and methods for making same
Sari et al. The Stability Study of Electrochemical Aptasensor to Detect SARS-CoV-2 Spike Protein and Its Application for Clinical Samples of Nasopharyngeal Swab
JP2012515893A5 (hr)
HRP20200476T1 (hr) Prognostički postupak i pribor koristan za navedeni postupak
UA138712U (uk) Спосіб прогнозування розвитку остеоартрозу
UA131135U (uk) Спосіб прогнозування розвитку остеоартрозу